


European Reference Network

for rare or low prevalence complex diseases

Network

Vascular Diseases (VASCERN)



Venous malformation

Final Approved Patient Pathway by the Vascular Anomalies (VASCA) Working Group – 29/04/2020

VASCERN VASCA working group Members: Miikka Vikkula, Laurence M. Boon, Andrea Diociaiuti, Veronika Dvorakova, May El Hachem, Nader Ghaffarpour, Alan Irvine, Friedrich Kapp, Kristiina Kyrklund, Jochen Rößler, Päivi Salminen, Caroline Van Den Bosch, Carine van der Vleuten, Leo Schultze Kool

Cooperating Guests: Anne Dompmartin, Eulalia Baselga Torres,

Disclaimer

- This document is an opinion statement reflecting strategies put forward by experts and patient representatives involved in the Vascular Anomalies (VASCA) Rare Disease Working Group of VASCERN.
- It is preferable that patients be evaluated in a multidisciplinary center specialized in the diagnosis and management of vascular anomalies.
- This pathway is issued on 29/04/2020 and will be further validated and adjusted as needed.
- Responsibility for care of individual patients remains with the treating physician.

Dieses Dokument wurde am 05.12.2022 von Dr. Friedrich Kapp für das Zentrum für Gefäßfehlbildungen (Uniklinik Freiburg) für das FZSE Freiburg geprüft, es war keine Kommentierung notwendig. Eine gemeinsame Überprüfung und Diskussion wird unabhängig hiervon in VASCA-WG erfolgen.





https://vascern.eu


Suspected Venous Malformation

Histology:

- VM : dilated veins, sparse vascular smooth muscle cells
- GVM : veins surrounded by glomus cells
- Maffucci syndrome : spindle cell hemangioma
- VVM: clusters of venus-like channels, GLUT 1+

VM :Venous Malformations GVM: Clomuvenous Malformations VVM: Verrucous Venous Malformations

- Blue or skin coloured swelling; sometimes mucosal lesion
- Typically empties with compression and fills up in dependent position
- Painful at awakening or after exercise. For extended period if local thrombosis (1 to 2 weeks)
 - Sometimes : firm, painful on palpation and/or palpable phleboliths
 No thrill, not warm
 - Number of lesions, associated anomalies and/or limb hypo / hypertrophy
 - Family history
 - Doppler ultrasound to confirm diagnosis & exclude fast flow
 MRI if diagnosis unclear
 - Biopsy rarely needed for differential diagnosis



Investigations

Treatment

Associated Genes


Clinical evaluation

LEGEND:





https://vascern.eu





palpation

Seizures, headaches, cerebral

Germline KRIT 1/CCM1

hemorrhages, focal neurological deficit.

С


Gathering the best expertise in Europe to provide accessible cross-border healthcare to patients with rare vascular diseases



https://vascern.eu

Cerebral MRI : cavernoma

Venous Malformation Diagnostic Work-Up continued For all types of VMs Small bluish or skin coloured lesions. Evaluate : Pain, aesthetic and function **Venous Malformation** 6 involving skin, mucosa or sometimes **Cutaneous Mucosal** muscle (VMCM) For all types of VMs Germline TEK Coagulation status (D Dimer, fibrinogen) Familial Multifocal MRI : Small lesions - if treatment is considered Less compressible Dark blue or purple plaques, nodules - to anticipate complications Number increases with time Superficial skin lesions Glomuvenous - to characterize the VM: size and extent (e.g. muscles, 7 Family history Painful on palpation Malformation (GVM) joints, bones, organs) No coagulation abnormality - if genital or perineal location MRI of the pelvis to rule out internal vascular malformation Germline Glomulin Dark blue or purple papules Often hyperkeratotic, Not painful on Hyperkeratotic Cutaneous



8

Capillaro-Venous

Malformation


(HCCVM)





https://vascern.eu

Venous Malformation Management/Treatment








https://vascern.eu

Chronic Consumptive Coagulopathy Management









VASCERN, the European Reference Network on Rare Multisystemic Vascular Diseases, is dedicated to gathering the best expertise in Europe in order to provide accessible cross-border healthcare to patients with rare vascular diseases (an estimated 1.3 million concerned). These include arterial diseases (affecting aorta to small arteries), arterio-venous anomalies, vascular malformations, and lymphatic diseases.

VASCERN currently consists of 30 highly specialised multidisciplinary Healthcare Providers (HCPs) from 11 EU Member States and of various European Patient Organisations and is coordinated in Paris, France.

Through our 5 Rare Disease Working Groups (RDWGs) as well as several thematic WGs and the ePAG- European Patient Advocacy Group, we aim to improve care, promote best practices and guidelines, reinforce research, empower patients, provide training for healthcare professionals and realise the full potential of European cooperation for specialised healthcare by exploiting the latest innovations in medical science and health technologies.

More information available at: https://vascern.eu





Co-funded by the Health Programme of the European Union